EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

PT Diastika Biotekindo Tbk (CHEK) fair value: what the stock is really worth

As of Sep 24, 2026: fair value of PT Diastika Biotekindo Tbk IDR 75, price IDR 130, upside -42.3%, quality 43 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · ID

PD Thin data Sep 24, 2026

PT Diastika Biotekindo Tbk

CHEK · JK

Weakest SetupStrongly overvalued and low quality.

!Fair value 75.00 IDR · Strongly overvalued (−42%)
!Quality 43/100
!Expensive Growth (revenue YoY +30.0 %/yr)
!Thin margins · 6.0% net margin (TTM)
✓Low debt
✓Ranks above peers (6/9)
!Narrow moat 41/100
!Insider activity 45/100
!Evidence only low, so the estimate is less certain
!Weak on future: 26 out of 100
!Weak on dividend: 12 out of 100
Watch PT Diastika Biotekindo Tbk for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

210.00 IDR 111.00 IDR Fair Value 75.00 IDR Jul 2025 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

14‑month range 111.00 IDR – 210.00 IDR · fair‑value band 55.80 IDR – 93.75 IDR · the 130.00 IDR price screens above the 75.00 IDR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.

Follow PT Diastika Biotekindo Tbk in your weekly email

Every Wednesday you see whether PT Diastika Biotekindo Tbk is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

PT Diastika Biotekindo Tbk engages in the sale of disposable or consumable medical goods and diagnostic equipment in Indonesia. It operates through Clinical Diagnostic Group and Life Science Group segments. The company offers various products for detecting, diagnosing, and monitoring human disease.

Show more

PT Diastika Biotekindo Tbk engages in the sale of disposable or consumable medical goods and diagnostic equipment in Indonesia. It operates through Clinical Diagnostic Group and Life Science Group segments. The company offers various products for detecting, diagnosing, and monitoring human disease. It also provides life science products that are processed from biological products. In addition, the company engages in general trading, laboratory equipment, research, medicine, export and import, pharmaceutical chemicals, services, electronics, and industrial activities. PT Diastika Biotekindo was founded in 1989 and is headquartered in Jakarta Timur, Indonesia. PT Diastika Biotekindo Tbk is a subsidiary of PT Optel Investama Mulia.

Stock analysis

PT Diastika Biotekindo Tbk (CHEK) currently trades at 130.00 IDR, while our model-based Fair Value estimate is 75.00 IDR, implying the stock looks roughly 73.3% overvalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of 120.48 IDR per share, and 1 of the 15 models we run sit above the 130.00 IDR price.

Bear case: the Dividend Discount group reads lowest at 12.12 IDR, and 14 of the 15 models stay below the price. Evidence for this calculation is low.

Scenario range: 55.80 IDR (bear) to 93.75 IDR (bull), the price of 130.00 IDR sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 43/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

PT Diastika Biotekindo Tbk reported revenue of 201B IDR in FY2025 versus 129B IDR in FY2023, a compound +24.9%/yr. Reported net income was 14.0B IDR in FY2025, compounding +1.6%/yr from FY2023.

Key figures

Market cap 535B IDR (≈ $29.9M) · P/S ratio 2.67 · Dividend yield 0.6% · Net margin 7.0% · Return on equity 8.2% · Return on assets (EBIT) 14.2% · Operating margin 7.0% · Revenue (TTM) 205B IDR.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 45 out of 100 (low confidence).

What moves the price

The share trades about 32% below its 52-week high and 17% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 35% fair-value upside, at −42%, CHEK screens richer than that median.

Fair Value models

Bear 55.80 IDR Fair Value 75.00 IDR Bull 93.75 IDR
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
EPV 45.00 IDR 51.38 IDR 56.89 IDR 71
Residual Income 40.48 IDR 41.97 IDR 43.23 IDR 69
EV/EBIT 76.34 IDR 100.26 IDR 124.19 IDR 66
All 15 models by family
Earnings-Based
Graham-Dodd 23.18 IDR 161.67 IDR 226.88 IDR 57
Lynch FV 66.25 IDR 94.64 IDR 123.03 IDR 55
PEG = 1.0 66.25 IDR 94.64 IDR 123.03 IDR 52
EPV 45.00 IDR 51.38 IDR 56.89 IDR 71
Dividend Discount
Gordon GGM 7.04 IDR 14.03 IDR 21.24 IDR 60
DDM Multi-Stage 7.04 IDR 12.12 IDR 14.80 IDR 61
Multiples
P/E Multiple 56.25 IDR 75.00 IDR 93.75 IDR 63
P/S Multiple 43.47 IDR 57.96 IDR 72.44 IDR 58
P/B Multiple 43.47 IDR 57.96 IDR 72.44 IDR 55
EV/EBIT 76.34 IDR 100.26 IDR 124.19 IDR 66
EV/Revenue 55.80 IDR 77.75 IDR 99.70 IDR 54
Asset-Based
NCAV (Graham) 25.66 IDR 34.38 IDR 51.32 IDR 54
Economic Profit
Residual Income 40.48 IDR 41.97 IDR 43.23 IDR 69
ROIC Compounder 45.00 IDR 51.47 IDR 65.41 IDR 66
Growth Earnings
Growth-Adj P/E 84.33 IDR 120.48 IDR 156.62 IDR 61

Open the full fair value analysis →

Notify me when CHEK reaches fair value

Put CHEK on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 43/100

Of which business quality 44 · Market factors (momentum, volatility) 34

Profitability 45
Margins and returns on capital today
Quality Growth 35
Are margins and returns improving?
Cashflow 0
Earnings quality: real cash, not paper profit
Fin. Strength 85
Balance sheet, leverage, solvency risk
Investment 33
Disciplined investing over empire-building
Low Volatility 55
Calm price path (market factor)
Momentum 32
Price trend over the last 3–12 months (market factor)
52W Momentum 14
Distance to the 52-week high (market factor)
Net Issuance 68
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 58/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: only 3 usable fiscal years, at least 4 required
not computed

CHEK screens 73% overvalued. Compare with McKesson Corporation →

Compare PT Diastika Biotekindo Tbk with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Distribution · 83 stocks

Beats the industry median on 5/8 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 43 · Bottom 25%
Fair Value upside −42% · Bottom 25%
Profitability
Return on equity (TTM) 8% · Above median
Return on assets 6% · Top 25%
Net margin (TTM) 6% · Top 25%
Operating margin (TTM) 7% · Above median
Growth and dividend
Revenue growth 5% · Above median
Dividend yield (TTM) 0.6% · Bottom 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 44
FUTURE (revenue growth)26 · sector 15
PAST (return on equity)33 · sector 27
HEALTH (low debt)100 · sector 96
DIVIDEND (yield)12 · sector 59

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Distribution stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
McKesson Corporation MCK $880.50 $819.31 −7%
Cencora, Inc COR $312.28 $211.07 −32%
Cardinal Health, Inc CAH $221.27 $141.77 −36%
Henry Schein, Inc HSIC $87.43 $76.86 −12%
Shanghai Pharmaceuticals Holding 601607 ¥16.06 ¥42.67 +166%
Sinopharm Group 1099 HK$15.06 HK$58.89 +291%
Galenica AG GALE CHF 83.45 CHF 61.79 −26%
Guangzhou Baiyunshan Pharmaceutical Holdings 600332 ¥19.67 ¥26.64 +35%
Jointown Pharmaceutical Group 600998 ¥4.89 ¥9.84 +101%
China National Medicines Corporation 600511 ¥26.11 ¥58.47 +124%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

PT Diastika Biotekindo Tbk · Fair Value
75.00 IDR −73%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "PT Diastika Biotekindo Tbk Fair Value". https://www.fairvalue-calculator.com/stock/CHEK

Frequently asked questions

Is PT Diastika Biotekindo Tbk (CHEK) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 75.00 IDR versus a price of 130.00 IDR, about −42% upside (overvalued).
What is the fair value of CHEK?
Our model-based fair value for PT Diastika Biotekindo Tbk is 75.00 IDR (as of Sep 24, 2026), built from audited fundamentals. The current price: 130.00 IDR.
What is the quality score of CHEK?
PT Diastika Biotekindo Tbk has a Quality Score of 43/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for PT Diastika Biotekindo Tbk (CHEK)?
Our model-based price target is the fair value of 75.00 IDR (as of Sep 24, 2026) from 15 valuation models. Cautious scenario 55.80 IDR, optimistic scenario 93.75 IDR. It is a calculation from audited fundamentals, not an analyst target.
What is the PT Diastika Biotekindo Tbk stock forecast for 2026?
Our models put fair value at 75.00 IDR, about −42% upside versus a price of 130.00 IDR (overvalued). Cautious scenario 55.80 IDR, optimistic scenario 93.75 IDR. The calculation is refreshed regularly with new filings.
What is the revenue of PT Diastika Biotekindo Tbk (CHEK)?
PT Diastika Biotekindo Tbk reported trailing-twelve-month revenue of about 205B IDR (latest available figure, as of Sep 24, 2026).
Does PT Diastika Biotekindo Tbk pay a dividend?
PT Diastika Biotekindo Tbk currently shows a dividend yield of about 0.60% relative to its recent price (as of Sep 24, 2026).
What is the intrinsic value of PT Diastika Biotekindo Tbk (CHEK)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For PT Diastika Biotekindo Tbk it is 75.00 IDR per share (as of Sep 24, 2026), against a price of 130.00 IDR. It is the blended result of 15 valuation models (cash flow, earnings, asset, dividend).
Is PT Diastika Biotekindo Tbk stock overvalued or undervalued in 2026?
As of Sep 24, 2026, CHEK trades above its calculated fair value: price 130.00 IDR, fair value 75.00 IDR, a gap of about −42% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CHEK?
No. The price is what the market pays today (130.00 IDR); the fair value is what the company's own numbers justify (75.00 IDR). For PT Diastika Biotekindo Tbk the two are 55.00 IDR per share apart. That gap is exactly why we show both numbers side by side.
How much is PT Diastika Biotekindo Tbk worth?
The market values PT Diastika Biotekindo Tbk at about 535B IDR (market capitalisation, as of Sep 24, 2026). Per share that is 130.00 IDR; our models calculate a fair value of 75.00 IDR per share.
What do the bullish and bearish scenarios say about CHEK?
Our models span a range for PT Diastika Biotekindo Tbk: cautious scenario 55.80 IDR, base 75.00 IDR, optimistic 93.75 IDR per share (as of Sep 24, 2026, price 130.00 IDR). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of PT Diastika Biotekindo Tbk (CHEK)?
Balance-sheet figures for PT Diastika Biotekindo Tbk (as of Sep 24, 2026): return on equity 8.2%. They feed the Quality Score of 43/100, which measures business quality independently of the share price.
How far is CHEK from its 52-week high?
PT Diastika Biotekindo Tbk trades at 130.00 IDR, about 32% below its 52-week high of 190.00 IDR and 17% above the low of 111.00 IDR (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of 75.00 IDR is for.
Which stocks are comparable to PT Diastika Biotekindo Tbk?
From the same area (Healthcare) we also value McKesson Corporation, Cencora, Inc, Cardinal Health, Inc, Henry Schein, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is PT Diastika Biotekindo Tbk stock attractive at the current price?
The data as of Sep 24, 2026: price 130.00 IDR, calculated fair value 75.00 IDR (−42%), Quality Score 43/100, from 15 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CHEK calculated?
We run PT Diastika Biotekindo Tbk through 15 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 75.00 IDR, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. PT Diastika Biotekindo Tbk itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of PT Diastika Biotekindo Tbk (CHEK)?
The closing price on Sep 24, 2026 was 130.00 IDR. Our model-based fair value is 75.00 IDR, about −42% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with PT Diastika Biotekindo Tbk right now?
The price sits above even our optimistic bull case (93.75 IDR). The favourable scenario is already priced in. Weak quality (43/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of PT Diastika Biotekindo Tbk

How large is the market capitalisation of PT Diastika Biotekindo Tbk (CHEK)?
The market capitalisation of PT Diastika Biotekindo Tbk is 535B IDR (≈ $29.9M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of PT Diastika Biotekindo Tbk (CHEK)?
The price-to-sales ratio of PT Diastika Biotekindo Tbk is 2.67 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of PT Diastika Biotekindo Tbk (CHEK)?
The dividend yield of PT Diastika Biotekindo Tbk is 0.6%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of PT Diastika Biotekindo Tbk (CHEK)?
The net margin of PT Diastika Biotekindo Tbk is 7.0% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of PT Diastika Biotekindo Tbk (CHEK)?
The return on equity (ROE) of PT Diastika Biotekindo Tbk is 8.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of PT Diastika Biotekindo Tbk (CHEK)?
On an EBIT basis the return on assets of PT Diastika Biotekindo Tbk is 14.2% (avg 3y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of PT Diastika Biotekindo Tbk (CHEK)?
The operating margin of PT Diastika Biotekindo Tbk is 7.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at PT Diastika Biotekindo Tbk (CHEK)?
Revenue at PT Diastika Biotekindo Tbk is growing +5.2% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at PT Diastika Biotekindo Tbk (CHEK)?
Earnings per share at PT Diastika Biotekindo Tbk are growing −29.2% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed

Watch PT Diastika Biotekindo Tbk in the live analysis

One click puts PT Diastika Biotekindo Tbk on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.